Cardiac hormones are c-Jun-N-terminal kinase 2-inhibiting peptides

Anticancer Research

Volumn 32, Issue 3, 2012, Pages 721-725

  Lane, Meghan L ^a   Santana, Omar ^a   Frost, Chelsea D ^a   Nguyen, Jennifer ^b   Guerrero, Jennifer ^a   Skelton IV, William P ^c   Skelton, Michelle ^a   Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b WICHITA STATE UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

c Jun N terminal kinase 2 (JNK2); Cardiac hormones; Mitogen activated protein kinase 9 (MAPK9); Natriuretic hormones; Stress activated protein kinase 1 alpha (SAPK1 )

Indexed keywords

ANTINEOPLASTIC AGENT; ATRIAL NATRIURETIC FACTOR; CARDIAC PEPTIDE HORMONE; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; PEPTIDE HORMONE; UNCLASSIFIED DRUG; VESSEL DILATOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROTEIN EXPRESSION; SMALL CELL CARCINOMA;

ATRIAL NATRIURETIC FACTOR; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LUNG NEOPLASMS; MITOGEN-ACTIVATED PROTEIN KINASE 9;

EID: 84858791307     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Kyriakas JM, Banerjee P, Nikolakaki E, Dai TA, Rubie EA, Ahmad MF, Avruch J and Woodgett JR: The stress-activated protein-kinase subfamily of c-Jun kinases. Nature 369: 156-160, 1994. (Pubitemid 24153440)
2. Heasley LE and Han SY: JNK regulation of oncogenesis. Mol Cells 21: 167-173, 2006.
3. Derijard R, Hibi M, Wu IH, Barrett T, Su B, Deng TL, Karin M and Davis RJ: Jnk1 - a protein-kinase stimulated by UV-light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76: 1025-1037, 1994. (Pubitemid 24106383)
4. Rosette C and Karin M: Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors. Science 274: 1194-1197, 1996. (Pubitemid 26389285)
5. Bost F, Dean N, McKay R and Mercola D: Activation of the Jun kinase/stress-activated protein kinase pathway is required for EGF-autocrine stimulated growth of human A549 lung carcinoma cells. J Biol Chem 272: 33422-33429, 1997. (Pubitemid 28023696)
6. Minden A, Lin A, McMahon M, Lange-Carter C, Derijard B, Davis RJ, Johnson GL and Karin M: Differential activation of ERK and JNK mitogen-activated protein kinases by RAF-1 and MEKK. Science 266: 1719-1723, 1994.
7. Juneja J, Cushman I and Casey PJ: G12 Signaling through c-Jun NH 2-terminal kinase promotes breast cancer cell invasion. PLoS One 6(11): e26085. Epub 2011 Nov 7.
8. Xia L, Dickens M, Raingeaud J, David RJ and Greenberg ME: Opposing effects of ERK and JNK-p 38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
9. Yang YM, Bost F, Charbono W, Dean N, McKay R, Rhim JS, Depatie C and Mercola D: c-Jun NH(2)-terminal kinase mediates proliferation and tumor growth of human prostate carcinoma. Clin Cancer Res 9: 391-401, 2003. (Pubitemid 36109757)
10. Bost F, Potapova O, Liu C, Zhang YM, Charbono W, Dean N, McKay R and Mercola D: High frequency regression of established human prostate carcinoma PC3 xenografts by systemic treatment with antisense Jun kinase. Prostate 38: 320-321, 1999.
11. Bost F, McKay R, Bost M, Potapova O, Dean NM and Mercola D: Jun kinase-2 isoform is preferentially required for epidermal growth factor-induced proliferation of human A549 lung carcinoma. Mol Cell Biol 19: 1938-1949, 1999. (Pubitemid 29098252)
12. Vesely DL: Natriuretic hormones. In: Seldin and Giebisch's The Kidney: Physiology and Pathophysiology, 4th edition. Alpern RJ, Herbert SC (eds.). Elsevier Inc. pp. 947-977, 2007.
13. Eichelbaum EJ, Sun Y, Alli AA, Gower WR Jr. and Vesely DL: Cardiac hormones and urodilatin eliminate up to 86% of human small cell lung carcinomas in mice. Eur J Clin Invest 38: 562-570, 2008. (Pubitemid 352019135)
14. Vesely DL, Eichelbaum EJ, Sun Y, Alli AA, Vesely BA, Luther SL, and Gower WR Jr.: Elimination of up to 80% of human pancreatic adenocarcinomas in athymic mice by cardiac hormones. In Vivo 21: 445-452, 2007. (Pubitemid 46901402)
15. Vesely DL, Vesely BA, Eichelbaum EJ, Sun Y, Alli AA and Gower WR Jr.: Four cardiac hormones eliminate up to two-thirds of human breast cancers in athymic mice. In Vivo 21: 973-978, 2007. (Pubitemid 350286323)
16. Sun Y, Eichelbaum EJ, Lenz A, Wang H and Vesely DL: Epidermal growth factor's activation of Ras is inhibited by four cardiac hormones. Eur J Clin Invest 40: 408-413, 2010.
17. Cellurale C, Sabio G, Kennedy NJ, Das M, Barlow M, Sandy P, Jacks T and Davis RJ: Requirement of c-Jun NH(2)-terminal kinase for Ras-initiated tumor formation. Mol Cell Biol 31: 1565-1576, 2011.
18. Sun Y, Eichelbaum EJ, Skelton WP IV, Lenz A, Regales N, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit RAS in human prostate cancer cells. Anticancer Res 29: 971-975, 2009.
19. Sun Y, Eichelbaum EJ, Lenz A, Skelton WP IV, Wang H and Vesely DL: Atrial natriuretic peptide and long-acting natriuretic peptide inhibit RAS in human prostate cancer cells. Anticancer Res 29: 1889-1893, 2009.
20. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 27: 1387-1392, 2007. (Pubitemid 46807213)
21. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Atrial natriuretic peptide and long-acting natriuretic peptide inhibit MEK 1/2 activation in human prostate cancer cells. Anticancer Res 27: 3813-3818, 2007.
22. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Vessel dilator and kaliuretic peptide inhibit activation of ERK 1/2 in human prostate cancer cells. Anticancer Res 26: 3217-3222, 2006. (Pubitemid 44701488)
23. Sun Y, Eichelbaum EJ, Wang H and Vesely DL: Atrial natriuretic peptide and long-acting natriuretic peptide inhibit ERK 1/2 in prostate cancer cells. Anticancer Res 26: 4143-4148, 2006. (Pubitemid 46031483)
24. Skelton WP IV, Pi G, Lenz A, Sun Y and Vesely DL: Cardiac hormones inhibit proliferation of pancreatic cancer but not normal cells. Eur J Clin Invest 40: 706-712, 2010.
25. Vesely BA, Alli AA, Song S, Gower WR Jr, Sanchez-Ramos J and Vesely DL: Four peptide hormones' specific decrease (up to 97%) of human prostate carcinoma cells. Eur J Clin Invest 35: 700-710, 2005. (Pubitemid 41640906)